Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Earnings release covers three and six months ended June 30, 2026.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Earnings release covers three and six months ended June 30, 2026
- Exhibit 99.1 contains Ligand’s financial results and accompanying management disclosures
- Information furnished under Regulation FD, limiting Section 18 Exchange Act liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $63.7M, up 34%, driven by royalty revenue of $48.0M, up 32% year over year
- Adjusted EPS $2.37, up 48%; GAAP EPS $2.22 versus $0.24, aided by investment gains
- 2026 adjusted EPS guidance raised to $9.00-$9.50; total revenue guidance unchanged at $270M-$310M
- XOMA acquisition adds over 120 assets and is expected to contribute $0.50-$1.50 per share to 2026-2027 adjusted EPS
- $700M zero-interest convertible notes expand acquisition capacity; approximately $700M remains deployable after XOMA closing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.